TY - JOUR T1 - Indirect comparison of efficacy of dupilumab <em>versus</em> mepolizumab and omalizumab for severe Type 2 asthma JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00306-2021 SP - 00306-2021 AU - Katrine Prætorius AU - Daniel P. Henriksen AU - Johannes M. Schmid AU - Pernille Printzlau AU - Lars Pedersen AU - Hanne Madsen AU - Ehm A. Andersson AU - Louise Klokker Madsen AU - Bo L. Chawes Y1 - 2021/01/01 UR - http://openres.ersjournals.com/content/early/2021/06/11/23120541.00306-2021.abstract N2 - Recently, several biologics have been introduced as add-on treatment for severe asthma [1]. The biologics target the underlying mechanism driving the disease and are recommended for specific phenotypes such as mepolizumab (anti-IL5) for severe eosinophilic asthma [2] and omalizumab (anti-IgE) for severe allergic asthma [3]; i.e. specific endotypes of Type 2 inflammation. Dupilumab (anti-IL4Rα) is a newer biologic recommended for severe asthma with Type 2 inflammation characterised by elevated blood eosinophils (≥150/μL) and/or fractional exhaled nitric oxide (FeNO≥25 ppb) [4]. Due to the IL4Rα activity of dupilumab it is likely to inhibit two Type 2 inflammatory pathways and therefore a patient can be eligible for more than one of the biologics, which is challenging in practice as no previous study has compared the efficacy of dupilumab with mepolizumab and omalizumab.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: Dr. Prætorius has nothing to disclose.Conflict of interest: Dr. Henriksen has nothing to disclose.Conflict of interest: Dr. Schmid has nothing to disclose.Conflict of interest: Dr. Printzlau has nothing to disclose.Conflict of interest: Dr. Pedersen has nothing to disclose.Conflict of interest: Dr. Madsen has nothing to disclose.Conflict of interest: Dr. Galijatovic has nothing to disclose.Conflict of interest: Dr. Madsen has nothing to disclose.Conflict of interest: Dr. Chawes has nothing to disclose. ER -